An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers
Latest Information Update: 28 May 2025
At a glance
- Drugs Lobeglitazone/D745/D150-Chong-Kun-Dang (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms CKD-383 FDI P1
- Sponsors Chong Kun Dang
Most Recent Events
- 21 May 2025 Status changed from recruiting to completed.
- 25 Nov 2024 New trial record